证券代码：002821 证券简称：凯莱英 公告编号：2025-001 凯莱英医药集团（天津）股份有限公司 关于回购进展的公告 一、 截至上月末的回购进展情况 截至 2024 年 12 月 31 日，公司累计通过回购专用证券账户以集中竞价方式 回购公司股份数量为 12,300,701 股，占公司 A 股总股本的 3.6161%，最高成交 价为 102.00 元/股，最低成交价为 71.65 元/股，合计支付的总金额为 999,644,601.56 元（不含交易费用）。本次回购股份符合公司回购方案及相关法 律法规要求。 二、其他说明 公司首次回购股份的时间、回购股份的数量及集中竞价交易的委托时段符合 《深圳证券交易所上市公司自律监管指引第 9 号——回购股份（2023 年修订）》 相关规定： （一）公司未在下列期间回购股份： 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于 2024 年 2 月 29 日召开 2024 年第二次临时股东大会、2024 年第二次 A 股类别股东大会及 2024年第二次H股类别股东大 ...

截至本公告披露日，James Randolph Gage先生未持有公司股份，其离任不会 影响公司生产经营活动的正常开展。 证券代码：002821 证券简称：凯莱英 公告编号：2024-095 凯莱英医药集团（天津）股份有限公司 关于高级管理人员退休离任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团(天津)股份有限公司(以下简称"公司")董事会近日收到公 司高级管理人员James Randolph Gage先生递交的书面离任报告。James Randolph Gage先生因到龄退休,申请辞去公司首席科学官(CSO)职务。根据《公司法》和《公 司章程》等有关规定，James Randolph Gage先生的书面离任报告自送达董事会之 日生效，James Randolph Gage先生离任后不在公司担任任何职务，公司将聘任其 为顾问继续提供技术指导和支持。 James Randolph Gage先生在任职期间，恪尽职守，带领公司技术团队攻坚克 难，筑牢企业技术壁垒；尤其是公司创立早期，充分发挥自身在医药化学领域的 研发经验和技术优势，持续优化 ...

证券代码：002821 证券简称：凯莱英 公告编号：2024-094 凯莱英医药集团（天津）股份有限公司 关于部分董事、高级管理人员和核心技术及业务人员 增持公司 A 股股份实施期限过半的公告 公司董事、高级管理人员和增持股份的核心技术及业务人员保证 公告内容真实、准确和完整，不存在虚假记载、误导性陈述或重大遗 漏。 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 特别提示： 1、 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于 2024 年 9 月 12 日披露了《关于部分董事、高级管理人员和核心技术及业务人员增持公 司 A 股股份计划的公告》（公告编号：2024-083）。公司部分董事、高级管理人员 和其他核心技术及业务人员拟自增持计划公告之日起 6 个月内增持公司 A 股股 份，本次增持总金额不低于人民币 2,000 万元（含）。本次增持计划不设置增持 价格区间，将根据公司股票价格波动情况及资本市场整体趋势择机实施本次增持 计划。 2、 截至本公告披露日，本次增持计划实施期限已过半，公司部分董事、高 级管理人员和其他核心技术及业务人员通过深圳证券交 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2024年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 2. 股份分 ...

证券代码：002821 证券简称：凯莱英 公告编号：2024-093 （一）公司未在下列期间回购股份： 凯莱英医药集团（天津）股份有限公司 关于回购进展的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于 2024 年 2 月 29 日召开 2024 年第二次临时股东大会、2024 年第二次 A 股类别股东大会及 2024年第二次H股类别股东大会，审议通过了《关于回购公司股份方案的议案》， 根据股份回购方案，公司将采用集中竞价交易的方式从二级市场回购公司 A 股 股份，本次回购股份的资金总额将不低于人民币 60,000 万元（含），且不超过人 民币 120,000 万元（含）；回购价格不超过 157 元/股。具体内容详见刊登在《证 券时报》、《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn）上的相关公告。 2024 年 6 月 6 日公司召开 2023 年度股东大会，审议通过了 2023 年年度权 益分派方案；本次权益分派股权登记日为 2024 年 6 月 27 日，除权除息日 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 证券代码：002821 证券简称：凯莱英 公告编号：2024-092 凯莱英医药集团（天津）股份有限公司 关于注销部分募集资金专户的公告 经中国证券监督管理委员会证监许可[2020]1912号文《关于核准凯莱英医药 集团（天津）股份有限公司非公开发行股票的批复》核准，公司于2020年9月向 特定投资者发行人民币普通股（A股）股票10,178,731.00股，每股发行价为227.00 元/股，募集资金总额为人民币2,310,571,937.00元，扣除券商承销费用（不含 税）32,696,772.70元，公司实际收到募集资金人民币2,277,875,164.30元，扣 除 其 他 发 行 费 用 人 民 币 2,914,508.24 元 ， 实 际 募 集 资 金 净 额 人 民 币 2,274,960,656.06元。上述资金到账情况业经容诚会计师事务所（特殊普通合伙） 出具容诚验字[2020]100Z0073号《验资报告》验证。公司对募集资金采取了专户 存储管理。 二、募集资金监管协议签订 ...

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Views - The company reported a revenue of 4.14 billion yuan for the first nine months of 2024, a year-on-year decline of approximately 35%, with a net profit attributable to shareholders of 710 million yuan [1] - In Q3 2024, the company achieved a revenue of 1.44 billion yuan, showing a year-on-year growth of 12.23% after excluding the impact of large orders, and a quarter-on-quarter increase of 11.21% [1] - The gross profit margin remained stable at 43.60% for the first nine months of 2024, with effective cost control measures mitigating resource consumption from large orders [1] - The small molecule business showed strong growth, with revenue reaching 1.19 billion yuan in Q3, reflecting an 18.89% year-on-year increase after excluding large orders [1] - The emerging business faced challenges, with revenue of 245 million yuan in Q3, a year-on-year decline of 13.26% [1] - The company is accelerating its global layout, with the first R&D and pilot base in Europe now operational, supporting the global supply chain [1] - New orders continued to grow, particularly from multinational pharmaceutical companies, indicating a strong market position in key areas [1] - The company expects net profits for 2024-2026 to be 1.064 billion yuan, 1.289 billion yuan, and 1.596 billion yuan, with growth rates of -53.1%, 21.1%, and 23.9% respectively [1] Financial Summary - For 2024, the company is projected to have a revenue of 5.954 billion yuan, a year-on-year decline of 23.9% [2] - The net profit attributable to shareholders for 2024 is estimated at 1.064 billion yuan, reflecting a year-on-year decrease of 53.1% [2] - The earnings per share (EPS) for 2024 is expected to be 2.89 yuan [2] - The price-to-earnings (P/E) ratio for 2024 is projected to be 29.6 times [2] - The return on equity (ROE) is expected to be 5.9% in 2024 [2]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price range of 82.08-95.76 CNY per share based on a projected P/E ratio of 24-28 for 2025 [1][8]. Core Insights - The company has shown steady growth in its small molecule CDMO business, while emerging businesses are expected to improve. The Q1-Q3 2024 revenue was 4.14 billion CNY, a year-on-year decrease of 35.14%, but a 4.48% increase when excluding large order impacts. The net profit attributable to shareholders was 710 million CNY, down 67.86% year-on-year [5][6]. - In Q3 2024, the company achieved revenue of 1.443 billion CNY, a year-on-year decline of 18.09%, but a quarter-on-quarter increase of 11.21%. The net profit for the same quarter was 211 million CNY, down 59.68% year-on-year [5][6]. - The small molecule CDMO business generated 3.387 billion CNY in revenue for Q1-Q3 2024, with a year-on-year increase of 7.71% when excluding large orders. The emerging business revenue was 745 million CNY, down 8.37% year-on-year [5][6]. Summary by Sections Financial Performance - The company's main revenue for 2022 was 10.255 billion CNY, which decreased to 7.825 billion CNY in 2023 and is projected to be 5.899 billion CNY in 2024. The net profit attributable to shareholders was 3.302 billion CNY in 2022, dropping to 2.269 billion CNY in 2023, with an expected further decline to 966 million CNY in 2024 [4][9]. - The earnings per share (EPS) were 8.98 CNY in 2022, decreasing to 6.17 CNY in 2023, and projected to be 2.63 CNY in 2024 [4][9]. Profitability Metrics - The overall gross margin for Q1-Q3 2024 was 43.60%, a decrease of 1.02 percentage points year-on-year. The small molecule CDMO business had a gross margin of 48.89%, which improved by 1.19 percentage points due to better cost control and an increase in clinical and commercial projects [6][7]. - The emerging business had a gross margin of 19.97%, down 12.99 percentage points, primarily due to a sluggish domestic market and ongoing capacity ramp-up [6][7]. Future Projections - For 2024-2026, the company is expected to achieve net profits of 966 million CNY, 1.259 billion CNY, and 1.595 billion CNY, respectively, with corresponding EPS of 2.63 CNY, 3.42 CNY, and 4.34 CNY [7][9]. - The projected P/E ratios for 2024, 2025, and 2026 are 31.57, 24.22, and 19.11, respectively [7][9].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][8] Core Views - The company has shown a good trend in new orders and is expected to recover its business in Q4 [1] - For the first three quarters of 2024, the company achieved a revenue of 4.14 billion yuan, a year-on-year decrease of 35.14%, but a 4.48% increase when excluding large order impacts [2] - The net profit attributable to shareholders for the same period was 710 million yuan, down 67.86% year-on-year [2] - The small molecule business has improved its gross margin, with a revenue of 3.39 billion yuan in the first three quarters, reflecting a 7.71% year-on-year increase when excluding large orders [3] Summary by Sections Financial Performance - In Q3 2024, the company reported a revenue of 1.44 billion yuan, a year-on-year decrease of 18.09%, but a 12.23% increase when excluding large orders [2] - The net profit for Q3 was 211 million yuan, down 59.68% year-on-year [2] - The small molecule business achieved a revenue of 1.19 billion yuan in Q3, with a year-on-year growth of 18.89% when excluding large orders [3] Business Segments - The small molecule business gross margin was 48.89% for the first three quarters, an increase of 1.19 percentage points year-on-year when excluding large orders [3] - The emerging business segment saw a revenue of 745 million yuan in the first three quarters, a decline of 8.37% year-on-year, but is expected to recover in Q4 [3] Market Position - The company's stock has underperformed relative to the CSI 300 index, with a 12-month performance of -43.0% [3] - The current stock price is 81.20 yuan, with a 52-week price range of 59.55-158.50 yuan [3] Future Outlook - Revenue projections for 2024-2026 are 5.89 billion, 6.99 billion, and 8.29 billion yuan respectively, with net profits expected to be 1.01 billion, 1.26 billion, and 1.51 billion yuan [5][6] - The company is focusing on optimizing its management and accelerating its global layout, with new projects expected to contribute positively in the future [3]

证券代码：002821 证券简称：凯莱英 公告编号：2024-091 凯莱英医药集团（天津）股份有限公司 关于回购进展的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于 2024 年 2 月 29 日召开 2024 年第二次临时股东大会、2024 年第二次 A 股类别股东大会及 2024年第二次H股类别股东大会，审议通过了《关于回购公司股份方案的议案》， 根据股份回购方案，公司将采用集中竞价交易的方式从二级市场回购公司 A 股 股份，本次回购股份的资金总额将不低于人民币 60,000 万元（含），且不超过人 民币 120,000 万元（含）；回购价格不超过 157 元/股。具体内容详见刊登在《证 券时报》、《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn）上的相关公告。 2024 年 6 月 6 日公司召开 2023 年度股东大会，审议通过了 2023 年年度权 益分派方案；本次权益分派股权登记日为 2024 年 6 月 27 日，除权除息日为 2024 年 6 月 28 日 ...